Welcome to our dedicated page for Essa Pharma news (Ticker: EPIX), a resource for investors and traders seeking the latest updates and insights on Essa Pharma stock.
ESSA Pharma Inc. (EPIX) is a clinical-stage biotechnology company that pioneered research into novel prostate cancer therapies targeting androgen receptor signaling. This page provides investors and industry observers with timely updates on corporate developments, including strategic reviews and historical clinical trial data.
Access verified press releases, financial filings, and official statements related to EPIX's discontinued clinical programs and ongoing business evaluations. Our curated news collection ensures efficient tracking of key milestones in the company's transition from active drug development to strategic repositioning.
Content includes updates on partnership opportunities, regulatory communications, and analyses of EPIX's specialized approach to oncology research. Bookmark this page for direct access to primary source materials and unfiltered corporate announcements, maintained for both professional investors and research stakeholders.
ESSA Pharma Inc. (EPIX) presented preclinical data on its androgen receptor (AR) N-terminal domain degraders, ANITAC™, at the AACR Annual Meeting 2022. The degraders effectively suppressed AR transcriptional activity and reduced prostate cancer cell viability in castration-resistant prostate cancer (CRPC) models. The data highlighted the ability of ANITAC™ to degrade various forms of AR expressed in CRPC patients. This innovative approach targets a significant challenge in treating advanced prostate cancer, where patients often develop resistance to existing therapies.
ESSA Pharma (NASDAQ: EPIX) updated on its clinical progress and reported financial results for Q1 FY2022, ending December 31, 2021. The company is advancing its lead candidate EPI-7386, with ongoing Phase 1a and Phase 1/2 studies for metastatic castration-resistant prostate cancer. Notable financial results included a net loss of $9.1 million ($0.21 per share), up from $6.5 million the previous year. ESSA's cash reserves stood at $189.2 million, supporting exploration into 2024. Upcoming updates on EPI-7386 are anticipated in the first half of 2022.
ESSA Pharma Inc. (NASDAQ: EPIX) has initiated a Phase 1/2 clinical trial for EPI-7386, a novel N-terminal domain androgen receptor inhibitor, in combination with enzalutamide for patients with metastatic castration-resistant prostate cancer (mCRPC). The trial, beginning with 30 patients, aims to assess safety, tolerability, and preliminary efficacy. The second phase will compare the combination treatment against enzalutamide alone in 120 patients. This study follows EPI-7386's previous Phase 1 trial and reflects ESSA's commitment to advancing prostate cancer therapies.
ESSA Pharma Inc. (NASDAQ: EPIX) reported a corporate update and financial results for the fiscal year ending September 30, 2021. The company posted a net loss of $36.8 million ($0.96 per share), compared to a loss of $23.4 million in 2020. ESSA highlighted progress in its lead candidate EPI-7386 for metastatic castration-resistant prostate cancer, including favorable clinical data and collaborations with major pharmaceutical companies like Janssen, Astellas, and Bayer for upcoming combination studies. Cash reserves of $195 million are anticipated to support operations into 2024.
ESSA Pharma Inc. (NASDAQ: EPIX) announced participation in three virtual investor conferences on November 8, 2021. David R. Parkinson, President and CEO, along with COO Peter Virsik and CFO David S. Wood, will host one-on-one meetings. The events include the Jefferies London Healthcare Conference on November 18, Piper Sandler 33rd Annual Healthcare Conference on November 22, and Evercore ISI HealthCONx Conference on December 2. Webcasts will be available on ESSA's website for 90 days post-event.
ESSA Pharma Inc. (NASDAQ: EPIX) presented preclinical data on EPI-7386, a leading prostate cancer treatment, at the 2021 Prostate Cancer Foundation Scientific Retreat on October 28-29, 2021. The data confirm EPI-7386's binding to the N-terminal domain of the androgen receptor, a region not targeted by existing therapies. The compound is undergoing a Phase 1 clinical trial for metastatic castration-resistant prostate cancer (mCRPC) and has received Fast Track designation from the U.S. FDA. Additional details are available on ESSA's website.
ESSA Pharma Inc. (NASDAQ: EPIX) presented preclinical data on EPI-7386, a novel androgen receptor N-terminal domain inhibitor for prostate cancer treatment, at the 2021 AACR-NCI-EORTC Virtual Conference. The studies demonstrate EPI-7386's binding mechanism to the androgen receptor's N-terminal domain, confirming its unique anti-cancer activity. The data also indicate that EPI-7386 can inhibit AR-driven biology, including AR splice variant activity. The company plans to initiate Phase 1/2 combination trials with antiandrogens for metastatic castration-resistant prostate cancer.
ESSA Pharma Inc. (Nasdaq: EPIX) and Caris Life Sciences have launched a Precision Development program aimed at enhancing the clinical trial for EPI-7386, a treatment for metastatic castration-resistant prostate cancer (mCRPC). The collaboration will utilize Caris' Whole Transcriptome and Whole Exome Sequencing technologies to analyze patient blood samples, enabling better characterization of tumor profiles. This partnership is expected to identify specific patient tumor biological subpopulations, potentially improving the efficiency of EPI-7386 development.
ESSA Pharma Inc. (NASDAQ: EPIX), a clinical-stage pharmaceutical company dedicated to prostate cancer treatments, announces that CEO David R. Parkinson will present at two upcoming virtual investor conferences. Key details include the H.C. Wainwright Annual Global Investment Conference on September 13, 2021, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21, 2021. Investors can access webcasts on ESSA's website, with archives available for 90 days post-event.
ESSA Pharma Inc. (NASDAQ: EPIX) announced a corporate update alongside its fiscal Q3 2021 financial results. For the quarter ended June 30, 2021, the company reported a net loss of $8.8 million, compared to $4.9 million in the same quarter of 2020. The increase in losses reflects higher R&D expenditures of $6.2 million due to ongoing Phase 1a clinical trials for EPI-7386, a novel therapy for metastatic castration-resistant prostate cancer (mCRPC). ESSA's cash reserves stand at $202 million, offering a runway into 2024 as it advances clinical trials and collaborations.
FAQ
What is the current stock price of Essa Pharma (EPIX)?
What is the market cap of Essa Pharma (EPIX)?
